Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Antibody; Neisseria meningitidis

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 86741 refers to a laboratory test specifically designed to measure antibodies against Neisseria meningitidis, a bacterium responsible for causing severe infections in the central nervous system and bloodstream. This bacterium is known for its highly contagious nature, primarily spreading through respiratory droplets found in saliva and mucus. The onset of symptoms associated with infections caused by N. meningitidis is typically sudden and can manifest as fever, headache, stiff neck, nausea, vomiting, skin rash, sensitivity to light, and confusion. The test focuses on detecting IgG antibodies, which include serogroups A, C, W-135, and Y. It serves a dual purpose: assessing the immune response following vaccination and evaluating individuals who may have an immune deficiency. Importantly, this test is not intended for diagnosing acute infections or determining serotype. To perform the test, a blood sample is collected through a separately reportable venipuncture, and the serum is analyzed using a quantitative multiplex bead assay, which allows for precise measurement of the antibody levels present in the sample.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The test coded as CPT® 86741 is indicated for specific clinical scenarios where the measurement of antibodies against Neisseria meningitidis is necessary. The following conditions warrant the performance of this laboratory test:

  • Assessment of Immune Response to Vaccination This test is utilized to evaluate the immune response in individuals who have received a vaccination against Neisseria meningitidis, helping to determine the effectiveness of the vaccine.
  • Evaluation of Suspected Immune Deficiency The test may be performed on patients who are suspected of having an immune deficiency, providing insight into their ability to produce antibodies against this pathogen.

2. Procedure

The procedure for conducting the test associated with CPT® 86741 involves several key steps that ensure accurate measurement of Neisseria meningitidis antibodies. The following outlines the procedural steps:

  • Step 1: Patient Preparation Prior to the test, the patient may be instructed to avoid certain medications or supplements that could interfere with antibody levels, although specific instructions should be provided by the healthcare provider.
  • Step 2: Venipuncture A qualified healthcare professional performs a venipuncture to obtain a blood sample from the patient. This step is crucial as the serum obtained from the blood is necessary for the subsequent analysis.
  • Step 3: Serum Separation After blood collection, the sample is processed to separate the serum from the cellular components. This is typically done by centrifugation, which allows for the clear serum to be collected for testing.
  • Step 4: Quantitative Multiplex Bead Assay The serum is then subjected to a quantitative multiplex bead assay, a sophisticated laboratory technique that enables the simultaneous measurement of multiple antibody levels, specifically targeting the IgG antibodies for serogroups A, C, W-135, and Y.
  • Step 5: Result Interpretation Once the assay is complete, the results are analyzed and interpreted by laboratory personnel, providing valuable information regarding the patient's immune response to Neisseria meningitidis.

3. Post-Procedure

After the procedure associated with CPT® 86741, patients may experience minimal discomfort at the venipuncture site, which typically resolves quickly. There are no specific post-procedure care instructions required for this test, but patients should be advised to monitor the site for any unusual symptoms, such as excessive bleeding or signs of infection. The results of the antibody test will be communicated to the healthcare provider, who will discuss the findings with the patient and determine any necessary follow-up actions based on the results.

Short Descr NEISSERIA MENINGITIDIS
Medium Descr ANTIBODY NEISSERIA MENINGITIDIS
Long Descr Antibody; Neisseria meningitidis
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 2
CCS Clinical Classification 235 - Other Laboratory
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
91 Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
Date
Action
Notes
1993-01-01 Added First appearance in code book in 1993.
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"